The weekly litigation news digest is live. Subscribe now

IP Verse

Crystalline Forms Of N-(4-(4-(Cyclopropylmethyl) Piperazine-1-Carbonyl)Phenyl)Quinoline-8-Sulfonamide - EP3713919

The patent EP3713919 was granted to Agios Pharmaceuticals on Aug 2, 2023. The application was filed on Nov 21, 2018 under application number EP18821779A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3713919

AGIOS PHARMACEUTICALS
Application Number
EP18821779A
Filing Date
Nov 21, 2018
Status
Granted And Under Opposition
Jun 30, 2023
Publication Date
Aug 2, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
BOTTI & FERRARIMay 2, 2024BOTTI & FERRARIADMISSIBLE
SANDOZMay 2, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2011002817
DESCRIPTIONWO2016201227
INTERNATIONAL-SEARCH-REPORTUS8785450
INTERNATIONAL-SEARCH-REPORTWO2016201227
OPPOSITIONEP3307271
OPPOSITIONUS8785450
OPPOSITIONWO2012151451
OPPOSITIONWO2016201227

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents